Deep Bio
Deep Bio and Visiopharm announce a collaborative integration of a clinical-grade AI prostate cancer solution with a leading digital pathology platform
Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partners...
Deep Bio Inc. successfully integrates DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs
A CASE STUDY OF DEEPDX® PROSTATE FROM DEEP BIO DEEPDX® PROSTATE FROM DEEP BIO DeepDx® Prostate is a clinically validated and CEmarked AI-based image analysis algorithm for prostate core needle biopsy ...
Deep Bio Acquires ISO 27001 Certification for Information Security Management
Deep Bio: Enhanced security and reliability through adherence to the globally recognized information security standards SEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022 Deep Bio, a pioneer in medical AI fo...
Deep Bio Acquires MDSAP Certification, Paving the Way for Global Expansion
SEOUL, SOUTH KOREA (PRWEB) AUGUST 16, 2022 Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced that it has been recently granted Medical Device Single Audit Program (MDSAP) ...
Deep Bio successfully integrates DeepDx® Prostate algorithm into HALO AP® platform from Indica Labs
DeepDx® prostate algorithm results shown in the HALO AP® platform. Deep Bio successfully integrates DeepDx® Prostate algorithm into HALO AP® platform from Indica Labs SEOUL, South Korea and ALBUQUERQU...
Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service
SEOUL, SOUTH KOREA (PRWEB) JULY 25, 2022 Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that its AI solution for grading the severity of prostate ca...
Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022
Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022 Five abstracts in prostate and breast cancers, Deep Bio’s main research areas, are present...
DeepBio’s AI-based prostate cancer pathology diagnosis wins new tech certification
DeepBio has announced that its deep learning-based prostate cancer pathology diagnosis technology using a Gleason grading system acquired NET (new excellent technology) certification on Tuesday...
- 1
- 2